Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT.

Inamoto, Yoshihiro; Valdés-Sanz, Nuria; Ogawa, Yoko; Alves, Monica; Berchicci, Luigi; Galvin, John; Greinix, Hildegard; Hale, Gregory A; Horn, Biljana; Kelly, Debra; Liu, Hien; Rowley, Scott; Schoemans, Helene; Shah, Ami; Lupo Stanghellini, Maria Teresa; Agrawal, Vaibhav; Ahmed, Ibrahim; Ali, Asim; Bhatt, Neel; Byrne, Michael; ... (2019). Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone marrow transplantation, 54(5), pp. 662-673. Nature Publishing Group 10.1038/s41409-018-0340-0

Text s41409-018-0340-0.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (794kB) | Request a copy

Ocular graft-versus-host disease (GVHD) occurs in more than half of patients who develop chronic GVHD after allogeneic hematopoietic cell transplantation (HCT), causing prolonged morbidity, which affects activities of daily living and quality of life. Here we provide an expert review of ocular GVHD in a collaboration between transplant physicians and ophthalmologists through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Recent updates in ocular GVHD, regarding pathophysiology, preclinical models, risk factors, prevention, screening, diagnosis, response criteria, evaluation measures, and treatment are discussed in this review. Ocular GVHD has at least three biological processes: lacrimal gland dysfunction, meibomian gland dysfunction, and corneoconjunctival inflammation. Preclinical models have found several novel pathogenic mechanisms, including renin angiotensin system and endoplasmic reticulum stress signaling that can be targeted by therapeutic agents. Many studies have identified reliable tests for establishing diagnosis and response assessment of ocular GVHD. Efficacy of systemic and topical treatment for ocular GVHD is summarized. It is important for all health professionals taking care of HCT recipients to have adequate knowledge of ocular GVHD for optimal care.

Interest & Impact

Downloads

3 since deposited on 08 Jan 2019
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item